# The BPC-157 + TB-500 Research Literature, Read in One Sitting

> A long-form editorial reading of the preclinical and clinical literature on BPC-157, TB-500, and full-length thymosin beta-4. Mechanism, key studies, and the absence of a combination trial. For research purposes only.

## I. The peptides, sequence first

BPC-157 is a fifteen-residue pentadecapeptide: G-E-P-P-P-G-K-P-A-D-D-A-G-L-V, molecular formula C62H98N16O22, molecular weight 1419.55 Da, CAS 137525-51-0. It was first described as a fragment of a larger cytoprotective protein discovered in human gastric juice in the early 1990s; the three consecutive prolines at positions 3–5 are thought to drive its unusual stability in gastric acid [1][20].

TB-500 as sold by research-chemical suppliers is the synthetic acetylated heptapeptide Ac-L-K-K-T-E-T-Q-OH. Those seven residues correspond to residues 17–23 of the full forty-three-amino-acid thymosin beta-4 (Tβ4, UniProt P62328), and they constitute the central actin-binding helix that gives Tβ4 its principal cellular function [22].

This is the most important sentence on the page: the seven-amino-acid fragment marketed as TB-500 is not the same molecule as the forty-three-amino-acid thymosin beta-4 that has been studied in cardiac, corneal, dermal-wound, and Phase I intravenous human work. The fragment retains the LKKTETQ helix; it lacks the rest of the chain. The published efficacy data attributed to TB-500 in vendor literature were, in their original publications, generated with the full-length peptide [11][12][13][14][22]. Whether the fragment fully reproduces the full molecule's biology has not been formally demonstrated in head-to-head clinical work. The site reads the literature with this asymmetry in view throughout.

## II. Mechanism — BPC-157

The mechanistic profile of BPC-157, as built up from rodent and cell-culture work, is consistent and unusually broad. The peptide upregulates VEGFR2-PI3K-Akt-eNOS angiogenic signalling at injury sites, modulates the nitric oxide system across eNOS, nNOS and iNOS, and shifts macrophage polarisation toward an anti-inflammatory M2 phenotype [4][20].

In cultured rat Achilles tendon fibroblasts, Chang and colleagues reported in Molecules in 2014 that BPC-157 at 0.1–0.5 μg/mL dose- and time-dependently increased growth-hormone-receptor mRNA and protein expression up to sevenfold, and that co-incubation with growth hormone amplified proliferation and PCNA expression via JAK2 activation [2]. In a Sprague-Dawley rat Achilles transection model, Staresinic and colleagues had reported in Journal of Orthopaedic Research in 2003 that BPC-157 at 10 μg/kg or 10 ng/kg intraperitoneally accelerated tendon recovery on biomechanical, functional, microscopic and macroscopic endpoints [1].

Krivic and colleagues extended this work in 2006 to a tendon-to-bone detachment model, showing that BPC-157 at 10 μg/kg or 10 ng/kg promoted reattachment and counteracted the negative effect of concomitant corticosteroid administration [3]. Brcic and colleagues showed in 2009 that BPC-157 modulated angiogenesis in crushed and transected muscle and tendon in rats, with increased CD34/FVIII-positive vasculature and VEGF expression at injury sites — although, instructively, BPC-157 produced no direct angiogenic effect in isolated cell cultures [4].

## III. Mechanism — TB-500 fragment and full-length Tβ4

Thymosin beta-4 is the principal G-actin-sequestering peptide in mammalian cells. A foundational structural-biochemistry literature, including work by Safer and colleagues at Journal of Biological Chemistry in the early 1990s, established that the LKKTETQ helix binds monomeric G-actin in one-to-one stoichiometry, sequestering on the order of forty to fifty percent of the cellular monomeric actin pool and regulating actin-filament dynamics that govern cell migration [22].

The LKKTETQ motif is the rationale for the TB-500 fragment. Trim the rest of the chain and the actin-binding helix remains. What the fragment does not necessarily inherit is the rest of Tβ4's intracellular and extracellular signalling. Bock-Marquette and colleagues reported in Nature in 2004 that Tβ4 activates integrin-linked kinase (ILK) and the survival kinase Akt in cardiomyocytes, and that intraperitoneal and intracardiac Tβ4 after coronary-artery ligation in mice reduced scar volume, preserved cardiac function, and increased myocyte survival [9]. Smart and colleagues followed in Nature in 2007 with the demonstration that Tβ4 mobilises adult epicardial progenitor cells, restores their pluripotency, and triggers differentiation into smooth muscle, endothelial and fibroblast lineages [10]. Both papers used full-length Tβ4.

A 2025 paper in Investigative Ophthalmology & Visual Science makes the distinction even sharper from the other direction. Nguyen and colleagues engineered a tandem Tβ4 (tTB4) construct carrying two LKKTETQ motifs in series and reported that it outperformed native Tβ4 in promoting corneal epithelial migration in vitro and in accelerating epithelial resurfacing and reducing scarring in alkali-burn mice [19].

## IV. Pharmacokinetics

He and colleagues at Frontiers in Pharmacology in 2022 published the cleanest BPC-157 pharmacokinetic profile to date, in Sprague-Dawley rats and beagle dogs after intramuscular dosing. Bioavailability was 14–19% in rats and 45–51% in dogs. T-max sat at roughly three minutes in rats and six to nine minutes in dogs. The plasma half-life ran under thirty minutes in both species. Metabolism produced six small peptide fragments terminating in free amino acids — notably proline — with urinary and biliary elimination [5][20].

For full-length Tβ4, Wang and colleagues published a Phase I first-in-human study in Journal of Cellular and Molecular Medicine in 2021. Eighty-four healthy Chinese volunteers received recombinant human Tβ4 (NL005) intravenously, single doses of 0.05–25 μg/kg in the SAD cohort and 0.5–5.0 μg/kg/day for ten days in the MAD cohort. No dose-limiting toxicities, no serious adverse events, dose-proportional pharmacokinetics with terminal half-life increasing at higher doses [14].

The seven-amino-acid TB-500 fragment has not been the subject of a published human pharmacokinetic study. Its plasma half-life is presumed shorter than full-length Tβ4 because it lacks the chain extensions that contribute to plasma stability, but that presumption is not formally measured.

## V. Human evidence — what exists

For BPC-157, the human record is small and mostly from a single investigator group. A 2025 narrative review by McGuire and colleagues catalogues three published reports: Lee and Padgett's 2021 intra-articular knee series (14 of 16 patients, 87.5% pain relief); Lee and colleagues' 2024 intravesicular bladder injection in twelve women with interstitial cystitis previously unresponsive to pentosan polysulfate (80–100% symptom resolution); and Lee and Burgess's 2025 single-arm intravenous infusion in healthy volunteers up to 20 mg (good tolerability and clearance within twenty-four hours) [6][25]. All three were small, uncontrolled, and from the same group. Vasireddi and colleagues' 2025 systematic review in HSS Journal identified thirty-six BPC-157 articles from 1993–2024 — thirty-five preclinical, one clinical [7].

For full-length Tβ4 the record is more substantial. Guarnera and colleagues published a multi-centre European Phase II trial in seventy-two patients with venous stasis ulcers in 2007, reporting an approximately one-month acceleration of wound closure and a clean tolerability profile [12]. The corneal programme has been documented across Phase II and Phase III work on RGN-259: Sosne and colleagues published a fifty-six-day Phase II trial in Cornea in 2015 in patients with severe dry eye disease, with a 35.1% reduction in ocular discomfort and a 59.1% reduction in total corneal fluorescein staining versus vehicle at day 56 [13]. A 2023 Phase III trial in neurotrophic keratopathy met its healing and comfort endpoints; the commercial SEER-3 Phase III at HLB Therapeutics, in contrast, missed its primary endpoint [14a].

Kleinman and Sosne's 2016 review extends the picture across dermal healing — normal rats and mice, steroid-treated rats, diabetic mice, aged mice, and Phase II trials in pressure ulcers, venous stasis ulcers, and epidermolysis bullosa [16]. Santra and colleagues reported in Glia in 2012 that Tβ4 administered twenty-four hours or more after embolic stroke in young adult rats acted as a neurorestorative agent — increasing oligodendrocyte progenitor differentiation in the subventricular zone and corpus callosum via p38 MAPK [17]. Goldstein and colleagues' 2012 expert review remains a useful one-document synthesis of Tβ4 as a regenerative peptide [18].

## VI. Newer rodent work, 2024–2025

Bajramagic and colleagues published a 2024 review in Pharmaceuticals summarising BPC-157 in rat intestinal anastomosis models — esophagogastric, colocolonic, jejunoileal, ileoileal — with reduced leakage, increased burst pressure, less necrosis [8].

Demirtas and colleagues published a 2025 ischemia-reperfusion study in Medicina in twenty-four Wistar rats. BPC-157 at 20 μg/kg intraperitoneally reduced histologic damage in liver, kidney and lung, raised total antioxidant status, lowered total oxidative status [26].

Matek and colleagues published a 2025 study in Pharmaceutics in which BPC-157 administered perorally in drinking water (10 μg/kg/day or 10 ng/kg/day) closed the muscle-bone gap by twenty-one to twenty-eight days after surgical detachment of the quadriceps from femoral and iliac attachments in rats [21]. Perovic and colleagues' 2019 work on sacrocaudal spinal-cord compression in rats remains relevant: a single intraperitoneal dose of 200 μg/kg or 2 μg/kg at ten minutes post-injury produced functional recovery and reduced secondary injury pathology by day fifteen [20a].

## VII. The absent combination study

Despite the prominence of the Wolverine nickname in research-peptide marketing and athlete forums, neither the 2025 narrative review in Current Reviews in Musculoskeletal Medicine nor the 2025 HSS Journal systematic review on BPC-157 identified a peer-reviewed combination study of BPC-157 and TB-500 that defines a synergy ratio, a combined dose, or a shared endpoint [6][25][7]. The two compounds have largely non-overlapping mechanisms — BPC-157 as a local angiogenic and cytoprotective signal, Tβ4 as an intracellular actin-sequestrant and progenitor mobiliser — and that complementarity is the basis on which the blend is rationalised. The rationalisation is not the evidence.

## VIII. Safety signals to keep in view

Jozwiak and colleagues' 2025 review in Pharmaceuticals surveys BPC-157 and records no observed teratogenic, genotoxic, anaphylactic, or local toxic effects at high doses in Sprague-Dawley rats (up to 20 mg/kg intramuscularly) or beagle dogs (up to 10 mg/kg intramuscularly). The same review flags two theoretical safety concerns: VEGFR2-mediated angiogenesis could be problematic in malignant or pre-malignant tissue, and proline-derived reactive oxygen species are a possible downstream consequence [20]. Neither concern has been demonstrated in human studies. Neither has been excluded.

Tβ4's mobilisation of progenitor and endothelial cells raises a parallel theoretical question in tumour microenvironments. Again, theoretical — not demonstrated, not excluded. The Phase I record at 0.05–25 μg/kg intravenous and 0.5–5 μg/kg/day over ten days reported no serious adverse events [14]. The honest summary is that the Tβ4 safety record at studied doses is reassuring in the short term and undetermined in the long term, and that the seven-amino-acid TB-500 fragment has no equivalent published human safety record at all.

## References

[1] Staresinic M, et al. Gastric pentadecapeptide BPC 157 accelerates healing of transected rat Achilles tendon. J Orthop Res. 2003;21(6):976-983.
[2] Chang CH, et al. Pentadecapeptide BPC 157 Enhances the Growth Hormone Receptor Expression in Tendon Fibroblasts. Molecules. 2014;19(11):19066-19077.
[3] Krivic A, et al. Achilles detachment in rat and stable gastric pentadecapeptide BPC 157. J Orthop Res. 2006;24(5):982-989.
[4] Brcic L, et al. Modulatory effect of BPC 157 on angiogenesis. J Physiol Pharmacol. 2009;60 Suppl 7:191-196.
[5] He L, et al. Pharmacokinetics, distribution, metabolism, and excretion of BPC 157 in rats and dogs. Front Pharmacol. 2022;13:1026182.
[6] McGuire FP, et al. Regeneration or Risk? A Narrative Review of BPC-157. Curr Rev Musculoskelet Med. 2025;18(12):611-619.
[7] Vasireddi N, et al. Emerging Use of BPC-157 in Orthopaedic Sports Medicine: A Systematic Review. HSS Journal. 2025.
[8] Bajramagic S, et al. BPC 157 and Intestinal Anastomoses Therapy in Rats—A Review. Pharmaceuticals (Basel). 2024;17(8):1081.
[9] Bock-Marquette I, et al. Thymosin beta4 activates integrin-linked kinase and promotes cardiac cell migration, survival and cardiac repair. Nature. 2004;432(7016):466-472.
[10] Smart N, et al. Thymosin β4 induces adult epicardial progenitor mobilization and neovascularization. Nature. 2007;445(7124):177-182.
[11] Sosne G, Qiu P, Kurpakus-Wheater M. Thymosin beta 4: A novel corneal wound healing agent. Clin Ophthalmol. 2007;1(3):201-207.
[12] Guarnera G, et al. Thymosin beta-4 and venous ulcers. Ann N Y Acad Sci. 2007;1112:407-412.
[13] Sosne G, Dunn SP, Kim C. Thymosin β4 — Phase 2 dry eye. Cornea. 2015;34(5):491-496.
[14] Wang T, et al. First-in-human Phase I study of recombinant human thymosin β4. J Cell Mol Med. 2021;25(18):8698-8708.
[14a] Sosne G, Kim C, Kleinman HK. 0.1% RGN-259 — Phase III Neurotrophic Keratopathy. IJMS. 2023;24(1):554.
[16] Kleinman HK, Sosne G. Thymosin β4 Promotes Dermal Healing. Vitamins and Hormones. 2016;102:251-275.
[17] Santra M, et al. Thymosin β4 mediates oligodendrocyte differentiation by upregulating p38 MAPK. Glia. 2012;60(12):1826-1838.
[18] Goldstein AL, et al. Thymosin β4: a multi-functional regenerative peptide. Expert Opin Biol Ther. 2012;12(1):37-51.
[19] Nguyen J, et al. Engineered Tandem Thymosin Peptide Promotes Corneal Wound Healing. IOVS. 2025;66(14):31.
[20] Jozwiak M, et al. Multifunctionality and Possible Medical Application of the BPC 157 Peptide. Pharmaceuticals (Basel). 2025;18(2):185.
[20a] Perovic D, et al. BPC 157 in spinal cord injury rats. J Orthop Surg Res. 2019;14(1):199.
[21] Matek D, et al. BPC 157 in quadriceps muscle reattachment in rats. Pharmaceutics. 2025;17(1):119.
[22] Safer D, Elzinga M, Nachmias VT. Thymosin β4 and Fx — indistinguishable. J Biol Chem. 1991;266(7):4029-4032.
[24] Sosne G, Kleinman HK. Thymosin beta 4 and the eye: bench to bedside. Expert Opin Biol Ther. 2018;18(sup1):99-104.
[25] McGuire FP, et al. Regeneration or Risk? — combination commentary. Curr Rev Musculoskelet Med. 2025;18(12):611-619.
[26] Demirtas H, et al. Protective Effects of BPC 157 on Liver/Kidney/Lung after Lower-Extremity I-R Injury. Medicina (Kaunas). 2025;61(2):291.

---

For research purposes only. Not for human consumption. This site does not sell any product and is not affiliated with any vendor.